June 12, 2023
Life Sciences | Tea Leaves
  • A panel of Food and Drug Administration advisers on Friday unanimously endorsed an experimental Alzheimer’s drug that’s been shown to have modest success slowing the progression of the disease, clearing a hurdle for full agency approval. Leqembi could become the first treatment of its kind to receive traditional approval from the FDA, which is expected to make a final decision by early July. While drugs that treat specific symptoms of the disease have been authorized, Leqembi would be “the first disease-modifying agent for Alzheimer’s disease” to be fully approved by the agency, said Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation. (Articles here and here)